BIOMAT Database Logo BIOMAT Database Logo

The Eurevie Study: contrasting effect of piretanide and thiazides in mild to moderate hypertension. 1997

O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
Laboratoires Hoechst, Paris La Défense, France.

This study compares the loop diuretic piretanide 6 mg in a slow-release formulation (PIR) with hydrochlorothiazide 25 mg (HCT) and the fixed combination altizide 15 mg-spironolactone 25 mg (ALT-SP) in hypertension. 1105 mild to moderate hypertensive patients entered a three-week placebo wash-out period; 899 were randomized in a 6-month, double-blind, parallel group treatment phase; 800 completed the study. Primary end-points; serum potassium concentration and quality of life at one month; secondary end-points: ionic, renal and metabolic variables; blood pressure (BP) measurements. HCT and ALT-SP were compared only to PIR using Dunnett's or chi 2 tests. RESULTS No difference was found for the overall quality of life. No change of serum potassium concentration at one month was found in PIR while small decreases were detected with ALT-SP (-0.1 mM) and HCT (-0.26 mM). Serum creatinine concentration increased significantly in ALT-SP when compared to PIR. All the drugs were effective in reducing BP: HCT had a higher rate of responders than PIR with similar mean BP falls and ALT-SP induced greater falls in blood pressure. CONCLUSIONS PIR proves to be a potent antihypertensive drug without significant effect on serum electrolytes, plasma glucose and lipids. HCT was slightly more potent but induced a fall in serum potassium concentration with a significant risk of hypokalaemia. The addition of SP to ALT led to a more potent diuretic with a higher level of serum potassium and plasma creatinine disturbances.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D004232 Diuretics Agents that promote the excretion of urine through their effects on kidney function. Diuretic,Diuretic Effect,Diuretic Effects,Effect, Diuretic,Effects, Diuretic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006852 Hydrochlorothiazide A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. Dichlothiazide,Dihydrochlorothiazide,Esidrex,Esidrix,HCTZ,HydroDIURIL,Hypothiazide,Oretic,Sectrazide

Related Publications

O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
Comparison of slow-release piretanide and bendroflumethiazide in the treatment of mild to moderate hypertension.
January 1989, The Journal of international medical research,
O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
Thiazides and amiloride in treatment of moderate hypertension.
July 1983, British medical journal (Clinical research ed.),
O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
Comparison of thiazides and amiloride in treatment of moderate hypertension.
August 1983, British medical journal (Clinical research ed.),
O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
Comparison of thiazides and amiloride in treatment of moderate hypertension.
June 1983, British medical journal (Clinical research ed.),
O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
Efficacy of penbutolol and a combination of a low dose of penbutolol with piretanide in the treatment of mild to moderate hypertension.
January 1985, Pharmatherapeutica,
O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
Hypotensive effect of oxprenolol in mild to moderate hypertension: a multicentre controlled study.
January 1975, European journal of clinical pharmacology,
O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
Chronic effect of ketanserin in mild to moderate essential hypertension.
February 1986, Hypertension (Dallas, Tex. : 1979),
O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
The effects of piretanide capsules on blood pressure during ergometric and isometric work loads in patients with mild to moderate essential hypertension.
January 1985, Pharmatherapeutica,
O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
Efficacy of a low fixed-dose combination of penbutolol with piretanide in the treatment of mild to moderate hypertension: a double-blind study against placebo.
January 1986, Pharmatherapeutica,
O L Charansonney, and M Lièvre, and M Laville, and L Lion, and E Derobert, and N Visèle, and S Decourt, and M P de Rusunan, and J Luciani, and D Vasmant, and J P Boissel, and J P Grünfeld
Evaluating mild to moderate hypertension.
May 1999, The Nurse practitioner,
Copied contents to your clipboard!